Warning Incyte (INCY) optimists! Yao Wenqing just Unloaded 10,000 shares.; GW Pharmaceuticals Plc – American Depositary Share (GWPH) SI Increased By 14.67% – The Yomi Blog

Incyte Corporation (NASDAQ:INCY) Logo

GW Pharmaceuticals Plc – American Depositary Share (NASDAQ:GWPH) had an increase of 14.67% in short interest. GWPH’s SI was 2.61M shares in January as released by FINRA. Its up 14.67% from 2.28 million shares previously. With 478,900 avg volume, 6 days are for GW Pharmaceuticals Plc – American Depositary Share (NASDAQ:GWPH)’s short sellers to cover GWPH’s short positions. The SI to GW Pharmaceuticals Plc – American Depositary Share’s float is 10.4%. The stock increased 2.40% or $2.75 during the last trading session, reaching $117.41. About 679,130 shares traded or 34.96% up from the average. GW Pharmaceuticals plc (NASDAQ:GWPH) has declined 1.75% since January 8, 2018 and is downtrending. It has underperformed by 1.75% the S&P500. Some Historical GWPH News: 04/05/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Zenabis; 06/04/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Agrima Botanicals; 06/04/2018 – lsodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Agrima Botanicals; 19/04/2018 – GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 – SEC FILING; 27/04/2018 – INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome; 08/05/2018 – GW PHARMACEUTICALS PLC – QTRLY SHR LOSS 26.0 CENTS; 19/04/2018 – GW PHARMACEUTICALS PLC – PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018; 13/03/2018 – GW Pharmaceuticals Announces Receipt of Notices of Allowance by the United States Patent and Trademark Office (USPTO) for Five; 24/05/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Cannabidiol Isolate to Sundial; 14/05/2018 – Peak Health Announces Filing of Patent Applications for testing the “Bioactivity” of the Cannabidiol (CBD) molecule and publica

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Nasdaq.com which released: “Interesting GWPH Put And Call Options For August 16th – Nasdaq” on January 07, 2019, also Nasdaq.com with their article: “GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should Know – Nasdaq” published on December 24, 2018, Seekingalpha.com published: “A Good Time To Buy GW Pharmaceuticals – Seeking Alpha” on January 02, 2019. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Nasdaq.com and their article: “Why Marijuana Stock GW Pharmaceuticals Dropped 10.5% in November – Nasdaq” published on December 12, 2018 as well as Seekingalpha.com‘s news article titled: “GW Pharmaceuticals Has Big Upside From Expected Revenues – Seeking Alpha” with publication date: December 18, 2018.

Among 6 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. GW Pharmaceuticals had 7 analyst reports since August 15, 2018 according to SRatingsIntel. The rating was maintained by Morgan Stanley on Friday, September 7 with “Overweight”. As per Monday, December 3, the company rating was maintained by Cantor Fitzgerald. Morgan Stanley maintained the shares of GWPH in report on Thursday, October 11 with “Overweight” rating.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.80 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $15.94 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It currently has negative earnings. The company??s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

Since July 9, 2018, it had 1 insider purchase, and 5 insider sales for $2.83 million activity. SWAIN PAULA J sold 10,000 shares worth $700,000. BIENAIME JEAN JACQUES had bought 1,000 shares worth $68,765 on Thursday, November 8. Trower Paul had sold 10,000 shares worth $700,000 on Wednesday, October 3. On Monday, July 9 Iyengar Vijay K sold $43,232 worth of Incyte Corporation (NASDAQ:INCY) or 606 shares. 1,000 shares were sold by Flannelly Barry P, worth $70,000 on Wednesday, October 3.

More notable recent Incyte Corporation (NASDAQ:INCY) news were published by: Nasdaq.com which released: “Nasdaq 100 Movers: FB, INCY – Nasdaq” on December 31, 2018, also Nasdaq.com with their article: “Nasdaq 100 Movers: PEP, INCY – Nasdaq” published on December 12, 2018, Nasdaq.com published: “Why Agenus Stock Is Spiking Today – Nasdaq” on January 07, 2019. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: Nasdaq.com and their article: “Merus Announces IND Clearance for MCLA-145 – Nasdaq” published on January 07, 2019 as well as Nasdaq.com‘s news article titled: “Incyte (INCY) Collaborates with Innovent for 3 Candidates – Nasdaq” with publication date: December 17, 2018.

Investors sentiment decreased to 1.19 in Q3 2018. Its down 0.04, from 1.23 in 2018Q2. It dived, as 37 investors sold Incyte Corporation shares while 125 reduced holdings. 66 funds opened positions while 126 raised stakes. 180.88 million shares or 1.39% less from 183.44 million shares in 2018Q2 were reported. Tributary Cap Mgmt Lc holds 22,100 shares. Burt Wealth Advisors invested in 0.07% or 2,188 shares. Cibc World Mkts has 13,982 shares for 0% of their portfolio. Paloma Prtn Co stated it has 0.01% in Incyte Corporation (NASDAQ:INCY). Dafna Capital Mngmt Limited Co holds 0.61% or 21,500 shares in its portfolio. Clarivest Asset Lc has invested 0% of its portfolio in Incyte Corporation (NASDAQ:INCY). Citadel Lc reported 1.61 million shares. Bancorporation Of Nova Scotia holds 59,400 shares. Price T Rowe Md reported 8.73 million shares. Fincl Architects stated it has 200 shares or 0% of all its holdings. Moreover, Wilbanks Smith And Thomas Asset Management Limited Liability Corp has 0% invested in Incyte Corporation (NASDAQ:INCY). Strs Ohio has 0% invested in Incyte Corporation (NASDAQ:INCY) for 16,105 shares. Badgley Phelps Bell has invested 0.02% of its portfolio in Incyte Corporation (NASDAQ:INCY). Bluemountain Capital Mngmt Lc invested in 53,465 shares. Moreover, Ameritas Invest Prns has 0.02% invested in Incyte Corporation (NASDAQ:INCY) for 7,128 shares.

The stock increased 0.93% or $0.69 during the last trading session, reaching $74.9. About 2.66 million shares traded or 61.06% up from the average. Incyte Corporation (NASDAQ:INCY) has declined 31.01% since January 9, 2018 and is downtrending. It has underperformed by 31.01% the S&P500. Some Historical INCY News: 17/04/2018 – Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2; 30/04/2018 – Delaware Healthcare Adds AMD, Cuts Incyte; 23/04/2018 – FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Act; 12/04/2018 – INTEGRAGEN SA ALINT.PA – CO’S PROPRIETARY MIRNA BIOMARKERS PREDICT EGFR TYROSINE KINASE INHIBITOR (EGFR-TKI) TREATMENT RESPONSE; 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pemb; 16/04/2018 – DYNAVAX INTERIM DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA® (; 10/04/2018 – NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB; 01/05/2018 – INCYTE 1Q LOSS/SHR 19C, EST. LOSS/SHR 15C; 30/04/2018 – FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and; 24/04/2018 – IMMUNOVACCINE – PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL

As disclosed in the Washington-based SEC, a public form for the sale of 10,000 shares of Incyte Corp by Yao Wenqing was filled. Yao Wenqing is the current EVP – Head of Discovery Chem of the Pinksheet-listed company. The public document was filled on January 08, 2019. The sold shares were sold at average $75.0 for share, and had a value of $750,000 U.S. Dollars. Yao Wenqing now indirectly has 0 shares. He also directly has 34409 shares. In total he holds a stake of 0.02%.

Analysts await Incyte Corporation (NASDAQ:INCY) to report earnings on February, 21. They expect $0.31 EPS, up 1,450.00% or $0.29 from last year’s $0.02 per share. INCY’s profit will be $65.97M for 60.40 P/E if the $0.31 EPS becomes a reality. After $0.20 actual EPS reported by Incyte Corporation for the previous quarter, Wall Street now forecasts 55.00% EPS growth.

Among 7 analysts covering Incyte (NASDAQ:INCY), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Incyte has $78 highest and $70 lowest target. $74.40’s average target is -0.67% below currents $74.9 stock price. Incyte had 8 analyst reports since July 13, 2018 according to SRatingsIntel. The rating was downgraded by JMP Securities on Wednesday, August 1 to “Market Perform”. The company was maintained on Monday, October 22 by Cantor Fitzgerald. Morgan Stanley downgraded Incyte Corporation (NASDAQ:INCY) on Friday, July 13 to “Equal-Weight” rating. On Wednesday, August 15 the stock rating was upgraded by RBC Capital Markets to “Outperform”. On Wednesday, July 18 the stock rating was maintained by Oppenheimer with “Perform”. The firm has “Buy” rating given on Thursday, January 3 by Guggenheim.

Incyte Corporation (NASDAQ:INCY) Institutional Positions Chart

Source: https://yomiblog.com/2019/01/08/warning-incyte-incy-optimists-yao-wenqing-just-unloaded-10000-shares-gw-pharmaceuticals-plc-american-depositary-share-gwph-si-increased-by-14-67/

« »